|
|
| | (3aR,6aR)-N-(4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide Basic information |
| | (3aR,6aR)-N-(4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide Chemical Properties |
| Boiling point | 675.6±55.0 °C(Predicted) | | density | 1.35±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 5 mg/mL (11.30 mM) | | pka | 13.59±0.20(Predicted) |
| | (3aR,6aR)-N-(4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide Usage And Synthesis |
| Biological Activity | Theliatinib (HMPL-309) is a potent EGFR inhibitor with a Ki value of 0.05 nM for EGFR and IC50 values of 3 nM and 22 nM for EGFR and EGFR T790M/L858R mutant, respectively. It is more than 50-fold selective for EGFR over 72 other kinases. | | in vitro | Compared with erlotinib or gefitnib, theliatinib has stronger binding affinity to wild-type EGFR and is more difficult to be replaced by ATP, which makes theliatinib have better target binding effect, and the EGFR-activated tumors have stronger antitumor activity. | | in vivo | Theliatinib has concentration-dependent antitumor activity in a series of patient-derived esophageal cancer xenograft models. But aberrant activation or genetic mutation of other targets such as PI3K and FGFR attenuates the antitumor activity of EGFR inhibitors, especially theliatinib. | | target | | Target | Value | WT EGFR
(Cell-free assay) | < td style="border-bottom: 1px dotted #ccc;padding: 5px;"> 3 nM EGFR T790M/L858R
(Cell-free assay) | 22 nM |
|
| | (3aR,6aR)-N-(4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxamide Preparation Products And Raw materials |
|